Avoid common mistakes on your manuscript.
Erratum to: Dermatol Ther (Heidelb) (2016) 6:69–75 DOI 10.1007/s13555-016-0093-x
In the original publication, in the Methods section, Scholl Fungal Nail Treatment is incorrectly attributed to Bayer Healthcare AG who is neither the manufacturer nor the market authorization holder. This should state Scholl Fungal Nail Treatment, Reckitt Benckiser Healthcare, UK.
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s13555-016-0093-x.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Ghannoum, M., Sevin, K. & Sarkany, M. Erratum to: Amorolfine 5% Nail Lacquer Exhibits Potent Antifungal Activity Compared to Three Acid-Based Devices Indicated for the Treatment of Onychomycosis: An In Vitro Nail Penetration Assay. Dermatol Ther (Heidelb) 6, 451 (2016). https://doi.org/10.1007/s13555-016-0124-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13555-016-0124-7